A Model‐Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A

Emicizumab is a bispecific antibody mimicking the cofactor function of activated coagulation factor VIII to prevent bleeds in patients with hemophilia A. The dose selection for the first‐in‐child phase III study of emicizumab was addressed by pediatric pharmacokinetic prediction using an adult/adole...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoneyama, Koichiro, Schmitt, Christophe, Chang, Tiffany, Dhalluin, Christophe, Nagami, Sayaka, Petry, Claire, Levy, Gallia G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Pediatric Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298840/
https://www.ncbi.nlm.nih.gov/pubmed/34545950
http://dx.doi.org/10.1002/jcph.1968

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298840/
https://www.ncbi.nlm.nih.gov/pubmed/34545950
http://dx.doi.org/10.1002/jcph.1968

Ejemplares similares